Data presented in a symposium session at the annual meeting of the European Association for the Study of Diabetes (EASD) provide insights into imeglimin, an investigational type 2 diabetes medicine.
The candidate, which has a unique mechanism of action, is being developed by French metabolic diseases biotech company Poxel (Euronext: POXEL), in collaboration with Japan’s Sumitomo Dainippon Pharma (TYO: 4506).
Detailed Phase III results from the TIMES 1 program were presented at the symposium, showing the candidate achieved robust efficacy compared with placebo. Top-line data released in April showed the trial met its primary and secondary endpoints.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze